MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis

Mei Juan Tu, Yu Zhuo Pan, Jing Xin Qiu, Edward Kim, Aiming Yu

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the United States. Better understanding of pancreatic cancer biology may help identify new oncotargets towards more effective therapies. This study investigated the mechanistic actions of microRNA-1291 (miR-1291) in the suppression of pancreatic tumorigenesis. Our data showed that miR-1291 was downregulated in a set of clinical pancreatic carcinoma specimens and human pancreatic cancer cell lines. Restoration of miR-1291 expression inhibited pancreatic cancer cell proliferation, which was associated with cell cycle arrest and enhanced apoptosis. Furthermore, miR-1291 sharply suppressed the tumorigenicity of PANC-1 cells in mouse models. A proteomic profiling study revealed 32 proteins altered over 2-fold in miR-1291-expressing PANC-1 cells that could be assembled into multiple critical pathways for cancer. Among them anterior gradient 2 (AGR2) was reduced to the greatest degree. Through computational and experimental studies we further identified that forkhead box protein A2 (FOXA2), a transcription factor governing AGR2 expression, was a direct target of miR-1291. These results connect miR-1291 to the FOXA2-AGR2 regulatory pathway in the suppression of pancreatic cancer cell proliferation and tumorigenesis, providing new insight into the development of miRNA-based therapy to combat pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)45547-45561
Number of pages15
JournalOncotarget
Volume7
Issue number29
DOIs
StatePublished - 2016

Fingerprint

MicroRNAs
Pancreatic Neoplasms
Carcinogenesis
Cell Proliferation
Hepatocyte Nuclear Factor 3-beta
Critical Pathways
Cell Cycle Checkpoints
Proteomics
Cause of Death
Neoplasms
Transcription Factors
Down-Regulation
Apoptosis
Cell Line
Therapeutics
Proteins

Keywords

  • AGR2
  • FOXA2
  • microRNA
  • MiR-1291
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology

Cite this

MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. / Tu, Mei Juan; Pan, Yu Zhuo; Qiu, Jing Xin; Kim, Edward; Yu, Aiming.

In: Oncotarget, Vol. 7, No. 29, 2016, p. 45547-45561.

Research output: Contribution to journalArticle

@article{56f04eb3781c46209b0de502ed788a22,
title = "MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis",
abstract = "Pancreatic cancer is the fourth leading cause of cancer death in the United States. Better understanding of pancreatic cancer biology may help identify new oncotargets towards more effective therapies. This study investigated the mechanistic actions of microRNA-1291 (miR-1291) in the suppression of pancreatic tumorigenesis. Our data showed that miR-1291 was downregulated in a set of clinical pancreatic carcinoma specimens and human pancreatic cancer cell lines. Restoration of miR-1291 expression inhibited pancreatic cancer cell proliferation, which was associated with cell cycle arrest and enhanced apoptosis. Furthermore, miR-1291 sharply suppressed the tumorigenicity of PANC-1 cells in mouse models. A proteomic profiling study revealed 32 proteins altered over 2-fold in miR-1291-expressing PANC-1 cells that could be assembled into multiple critical pathways for cancer. Among them anterior gradient 2 (AGR2) was reduced to the greatest degree. Through computational and experimental studies we further identified that forkhead box protein A2 (FOXA2), a transcription factor governing AGR2 expression, was a direct target of miR-1291. These results connect miR-1291 to the FOXA2-AGR2 regulatory pathway in the suppression of pancreatic cancer cell proliferation and tumorigenesis, providing new insight into the development of miRNA-based therapy to combat pancreatic cancer.",
keywords = "AGR2, FOXA2, microRNA, MiR-1291, Pancreatic cancer",
author = "Tu, {Mei Juan} and Pan, {Yu Zhuo} and Qiu, {Jing Xin} and Edward Kim and Aiming Yu",
year = "2016",
doi = "10.18632/oncotarget.9999",
language = "English (US)",
volume = "7",
pages = "45547--45561",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "29",

}

TY - JOUR

T1 - MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis

AU - Tu, Mei Juan

AU - Pan, Yu Zhuo

AU - Qiu, Jing Xin

AU - Kim, Edward

AU - Yu, Aiming

PY - 2016

Y1 - 2016

N2 - Pancreatic cancer is the fourth leading cause of cancer death in the United States. Better understanding of pancreatic cancer biology may help identify new oncotargets towards more effective therapies. This study investigated the mechanistic actions of microRNA-1291 (miR-1291) in the suppression of pancreatic tumorigenesis. Our data showed that miR-1291 was downregulated in a set of clinical pancreatic carcinoma specimens and human pancreatic cancer cell lines. Restoration of miR-1291 expression inhibited pancreatic cancer cell proliferation, which was associated with cell cycle arrest and enhanced apoptosis. Furthermore, miR-1291 sharply suppressed the tumorigenicity of PANC-1 cells in mouse models. A proteomic profiling study revealed 32 proteins altered over 2-fold in miR-1291-expressing PANC-1 cells that could be assembled into multiple critical pathways for cancer. Among them anterior gradient 2 (AGR2) was reduced to the greatest degree. Through computational and experimental studies we further identified that forkhead box protein A2 (FOXA2), a transcription factor governing AGR2 expression, was a direct target of miR-1291. These results connect miR-1291 to the FOXA2-AGR2 regulatory pathway in the suppression of pancreatic cancer cell proliferation and tumorigenesis, providing new insight into the development of miRNA-based therapy to combat pancreatic cancer.

AB - Pancreatic cancer is the fourth leading cause of cancer death in the United States. Better understanding of pancreatic cancer biology may help identify new oncotargets towards more effective therapies. This study investigated the mechanistic actions of microRNA-1291 (miR-1291) in the suppression of pancreatic tumorigenesis. Our data showed that miR-1291 was downregulated in a set of clinical pancreatic carcinoma specimens and human pancreatic cancer cell lines. Restoration of miR-1291 expression inhibited pancreatic cancer cell proliferation, which was associated with cell cycle arrest and enhanced apoptosis. Furthermore, miR-1291 sharply suppressed the tumorigenicity of PANC-1 cells in mouse models. A proteomic profiling study revealed 32 proteins altered over 2-fold in miR-1291-expressing PANC-1 cells that could be assembled into multiple critical pathways for cancer. Among them anterior gradient 2 (AGR2) was reduced to the greatest degree. Through computational and experimental studies we further identified that forkhead box protein A2 (FOXA2), a transcription factor governing AGR2 expression, was a direct target of miR-1291. These results connect miR-1291 to the FOXA2-AGR2 regulatory pathway in the suppression of pancreatic cancer cell proliferation and tumorigenesis, providing new insight into the development of miRNA-based therapy to combat pancreatic cancer.

KW - AGR2

KW - FOXA2

KW - microRNA

KW - MiR-1291

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84979924172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979924172&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9999

DO - 10.18632/oncotarget.9999

M3 - Article

C2 - 27322206

AN - SCOPUS:84979924172

VL - 7

SP - 45547

EP - 45561

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -